| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453587 | Lung Cancer | 2018 | 10 Pages |
Abstract
A rapid increase of the LMR was significantly associated with the effects of nivolumab monotherapy in our study cohort. Therefore, early change of the LMR may be used as a novel effective surrogate marker to decide on continuation of anti-PD-1 therapy.
Keywords
NivolumabPD-1ORRPD-L1ROCLCNECLMRNLREGFRPFsALKprogression-free survivaloverall survivalRECISTirAEsNon-small-cell lung cancerNon-small-cell lung cancer (NSCLC)NSCLCBrinkman IndexImmune-related adverse eventsAnaplastic lymphoma kinaseprogrammed cell death ligand 1Response Evaluation Criteria in Solid Tumorsobjective response rateLymphocyte-to-monocyte ratioNeutrophil-to-lymphocyte ratioSquamous cell carcinomaLarge cell neuroendocrine carcinomareceiver operating characteristicEpidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Katsutoshi Sekine, Shintaro Kanda, Yasushi Goto, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Noriko Motoi, Yuichiro Ohe,